Evaluating the Therapeutic Efficacy of Habb-e-Asgandh in Diabetic Peripheral Neuropathy, A Randomized Single Blind Standard Control Study.

Central Council of Research in Unani Medicine New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年4月4日

试验速览

暂无简介。

•Clinically diagnosed patients of Diabetic Peripheral Neuropathy with type 2 Diabetes mellitus, having fasting blood sugar (FBS) from 140mg/dl up to 200mg/dl and post prandial (PPS) level from 200mg/dl up to 300mg/dl.
•-Patients between the ages of 30 to 60 years.
•1. Patients irrespective of gender.
•2. Patients having blood urea, serum creatinine, SGOT, SGPT within normal limit.
•3. Patients willing to participate in the study and follow the instructions.

•1. Pregnant and lactating mothers
•2. Pathological status: cardiovascular disease, renal disease, hepatic disease.
•3. Patients below 30 years and above 60 years of age.
•ï??Complications of Diabetes other than Diabetic peripheral neuropathy.
•4. Causes of Neuropathy other than Diabetes.
•5. Patients who refuse to give the written consent for the study

发起方

Central Council of Research in Unani Medicine New Delhi